Nominum and CIRA Create “Cyber-Secure Schools” Initiative to Bring Powerful Cyber Protections to Schools Throughout Canada
Nominum™, an innovator of internet security solutions and services, and the Canadian Internet Registration Authority (CIRA), announced today that they have joined forces to deliver a powerful, cost-effective cloud security solution to K-12 schools, school boards and higher education institutions across Canada through a collaborative “Cyber-Secure Schools” initiative.
The Cyber-Secure Schools program aims to reduce malware risk, improve network performance and create safe online learning environments for teachers, students and administrators – as well as every device connected to the school network – through CIRA’s D-Zone DNS firewall powered by Nominum N2™ Secure Business.
Nominum and CIRA are already seeing rapid adoption of D-Zone by school boards across Canada, given the significant costs associated with cyberattacks, budget constraints, and the need for solutions that are easy to implement and manage. For example, the Wild Rose School Division in Rocky Mountain House, Alberta, has deployed the solution to protect its users from increasing incidents of ransomware and phishing attacks they see on their networks.
“Our district has a mobile-first strategy, driven by technology and learning strategies that are moving education beyond the classroom. Because of this, it’s critical that our network blocks malware and malicious content so students and teachers remain protected, no matter where they are,” said Jaymon Lefebvre, Director, IT Services for Wild Rose School Division. “This requires effective security that dynamically scales to meet growing demands and policy changes. The Nominum-CIRA Cyber-Secure Schools initiative and cloud security solution they provide ensures that the entire Wild Rose community is safeguarded from today’s dangerous threats.”
“Less than half of zero-day malware is detected by traditional anti-virus solutions, and since most malware uses DNS for command and control, our combined solution is an ideal first line of defense that complements any company’s security solution against emerging threats,” said Dave Chiswell, Vice President of Product Development for CIRA. “Through our partnership with Nominum we are delivering a better, more secure internet to schools and businesses throughout Canada, giving students, teachers and administrative staff assurances that educational activities taking place online are safe.”
Education Sector Hit Hardest by Ransomware, Driving the Need for Better Cybersecurity
U.S. government statistics show that the rate of ransomware attacks tripled in 2016 over 2015.1 Specifically, research conducted by the security ratings firm BitSight showed that ransomware strikes the education sector more than any other, with one in 10 schools having been hit with malware on their networks.2
“With cybercrime on the rise and schools facing budget and resource limitations, they are particularly vulnerable to cyberattacks that could cause long-term financial and operational damage,” said Arlen Frew, General Manager, Security Solutions for Nominum. “In today’s Digital Age, with more instruction and learning taking place online, it’s critical that schools have a powerful security infrastructure to keep students, teachers and other users protected. CIRA and Nominum are delivering enterprise-class security in a cost-effective solution that requires little hands-on maintenance – a combination that is missing from the education security marketplace.”
N2 Secure Business: Protecting SMBs in an Easily Managed Cloud Solution
Nominum N2 Secure Business is a ground-breaking cloud-based security solution that enables managed services providers like CIRA, as well as ISPs and telecom operators, to deliver a white-label security-as-a-service (SECaaS) solution to schools, government agencies and small and medium-sized business (SMB) customers. N2 Secure Business is quickly creating new revenue streams for these providers, which are now able to offer enterprise-class security in a solution that is ideally suited for the education sector from a cost and ease of management perspective.
The solution utilizes Nominum’s global DNS footprint and near real-time threat intelligence stream to discover and automatically block users from connecting to malicious domains and fills a critical market need for protection from ransomware, phishing and other malware in an easily managed solution that is suited to a small business budget. The technology also allows for simple management of content blocking, a requirement to ensure students in the K-12 environment are offered a safe and secure online experience.
N2-powered D-Zone DNS Firewall: The Ideal Hands-off Solution for K-12 and Higher Education Schools
The D-Zone DNS Firewall locates the technology in Canadian Internet Exchange Points to deliver a very high-performance recursive service, keep query data in Canada, help move more traffic onto low-cost, or free education and research networks and provide higher security. The Cyber-Secure Schools program further benefits schools by providing licensing models that recognizes the different user in a school board environment. And finally, schools (and businesses) can create, modify and grant different levels of access to content for students based on age-appropriate safe browsing polices.
The Canadian Internet Registration Authority (CIRA) manages the .CA top-level domain on behalf of all Canadians. CIRA also develops technologies and services that help support its goal of building a better online Canada. CIRA’s D-Zone Anycast DNS provides is the most comprehensive Canadian DNS solution available on the market, helping to improve security and performance for Canadian organizations. The CIRA team operates one of the fastest growing ccTLDs, a high-performance global DNS network, and one of the world’s most advanced back-end registry solutions. CIRA helps to support the Canadian Internet community through investments in Internet Exchange Points, the Canada Internet Forum, and the CIRA Community Investment Program.
Nominum™ is a pioneer and global leader in internet security and services innovation. The Silicon Valley company provides an integrated suite of carrier-grade DNS-based solutions that enable fixed and mobile operators, and managed services and web application providers to protect and enhance their networks, strengthen security for business and residential subscribers and offer innovative value-added services that can be monetized. The result is improved service agility, higher ARPU, increased brand loyalty and a strong competitive advantage. More than 130 service providers in over 40 countries trust Nominum to deliver a safe, customizable internet and promote greater value to over half a billion users. Nominum DNS software resolves 1.7 trillion queries around the globe every day—roughly 100 times more transactions than the combined daily volume of tweets, likes, and searches taking place on major web properties. For more information visit nominum.com.
Follow us on Twitter: @nominum https://twitter.com/nominum
Follow us on LinkedIn: https://www.linkedin.com/company/nominum
See us on YouTube: https://www.youtube.com/nominum
Nancy MacGregor, +1-415-309-5185
Om Business Wire
(c) 2018 Business Wire, Inc., All rights reserved.
Business Wire, a Berkshire Hathaway company, is the global leader in multiplatform press release distribution.
Følg saker fra Business Wire
Registrer deg med din epostadresse under for å få de nyeste sakene fra Business Wire på epost fortløpende. Du kan melde deg av når som helst.
Siste saker fra Business Wire
Phase 3 Data on Filgotinib in Biologic-Experienced Rheumatoid Arthritis to Be Presented at 2018 ACR/ARHP Annual Meeting20.10.2018 22:30 | Pressemelding
Gilead Sciences, Inc. (Nasdaq: GILD) and Galapagos NV (Euronext & NASDAQ: GLPG) today announced detailed results from the Phase 3 FINCH 2 clinical trial of filgotinib, an investigational, selective JAK1 inhibitor, in adults with moderately-to-severely active rheumatoid arthritis and prior inadequate response or intolerance to biologic agents. The data, which are being presented as a late-breaking poster at the 2018 American College of Rheumatology/Association of Rheumatology Health Professionals (ACR/ARHP) Annual Meeting in Chicago, suggest filgotinib has a potential role in addressing important unmet needs in the treatment of rheumatoid arthritis. Positive efficacy data from FINCH 2 were previously announced in September 2018. The data show statistically significant improvements in the proportion of patients achieving a range of clinical efficacy endpoints, including the proportion of patients achieving American College of Rheumatology 20 percent (ACR20, primary endpoint), 50 percent
Manchester United and True Religion Launch Denim Range19.10.2018 17:37 | Pressemelding
Manchester United (NYSE:MANU) and luxury denim brand True Religion have collaborated to launch a range of premium club branded denim wear. A first for the club, the new global partnership with the iconic American denim brand will see a range of men’s & women’s co-branded styles go on sale beginning 26th October in the club’s Megastore as well as online via United Direct and truereligion.com & eu.truereligion.com. The exclusive collection features jeans, shirts and jackets, including a highly desirable limited edition denim jacket embroidered with the club’s crest. Fans will have the opportunity to win a selection of clothing from the new range by visiting www.manutd.com/truereligion. Manchester United’s Group Managing Director, Richard Arnold, comments: “True Religion is a well-known, established name in fashion, creating unique designs without compromising on quality. The range we have collaborated on includes the same attention to detail and craftsmanship that has made True Religion
Arch Insurance Announces Strategic Leadership Changes19.10.2018 13:10 | Pressemelding
Arch Insurance today announced that Matt Shulman will assume the newly created role of CEO, Arch Insurance North America, effective January 1, 2019. In this role, he will lead Arch Insurance’s operations in the United States and Canada. He will report to Nicolas Papadopoulo, Chairman and CEO of Arch Worldwide Insurance Group. Mr. Shulman, who has more than 20 years of experience in the insurance industry, has been with Arch Insurance since 2009 and has served as the President and CEO of Arch Insurance Europe since 2016. “Matt brings significant U.S. and international experience to this role. Under his leadership, together with our senior team, Arch Insurance will continue to enhance our value proposition to our customers through a robust, diversified product portfolio, creative solutions and excellent service,” Mr. Papadopoulo said. Arch Insurance has also created a new organizational structure with three Chief Underwriting Officers (CUO) dedicated to specific lines of business. These
Takeda to Present Results from Phase 3 ALTA-1L Trial Highlighting Intracranial Efficacy of ALUNBRIG® (brigatinib) Versus Crizotinib in First-Line Advanced ALK+ Non-Small Cell Lung Cancer19.10.2018 12:00 | Pressemelding
Takeda Pharmaceutical Company Limited (TSE: 4502) today announced that intracranial efficacy data from the Phase 3 ALTA-1L (ALK in Lung Cancer Trial of BrigAtinib in 1 st Line) trial showed improved intracranial progression-free survival (PFS) and intracranial objective response rate (ORR) with ALUNBRIG (brigatinib) compared to crizotinib among anaplastic lymphoma kinase-positive (ALK+) non-small cell lung cancer (NSCLC) patients. Data for these secondary endpoints will be presented in a poster discussion at the European Society for Medical Oncology (ESMO) 2018 Congress on Friday, October 19 at 2:00 p.m. CET in Munich, Germany. These results further support ALUNBRIG as a potential treatment for adults with ALK+ locally advanced or metastatic NSCLC who had not received a prior ALK inhibitor. ALUNBRIG is currently not approved as first-line therapy for advanced ALK+ NSCLC. “ALK+ NSCLC often spreads to the brain, so having options that can clearly demonstrate efficacy both in the brain an
Vertex Receives European CHMP Positive Opinion for KALYDECO® (ivacaftor) to Treat Patients With Cystic Fibrosis Aged 12 to <24 months With Certain Mutations in the CFTR Gene19.10.2018 11:54 | Pressemelding
Vertex Pharmaceuticals (Europe) Limited today announces that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for KALYDECO® (ivacaftor) to include the treatment of people with cystic fibrosis (CF) aged 12 to <24 months who have at least one of the following nine mutations in their cystic fibrosis transmembrane conductance regulator (CFTR) gene: G551D, G1244E, G1349D, G178R, G551S, S1251N, S1255P, S549N or S549R. If the European Commission issues a favorable adoption of the EMA CHMP opinion for the extension of indication, ivacaftor will be the first and only medicine approved in Europe to treat the underlying cause of CF in patients aged 12 to <24 months, who have specific mutations in the CFTR gene. “Cystic fibrosis is a chronic, progressive disease that is present at birth, with symptoms often occurring in infancy, so early treatment is crucial to deliver the best possible outcomes for patients,” said Reshma Kewalr
Schlumberger Announces Third-Quarter 2018 Results19.10.2018 11:00 | Pressemelding
Schlumberger Limited (NYSE: SLB) today reported results for the third quarter of 2018. (Stated in millions, except per share amounts) Three Months Ended Change Sept. 30, 2018 Jun. 30, 2018 Sept. 30, 2017 Sequential Year-on-year Revenue $8,504 $8,303 $7,905 2% 8% Pretax operating income $1,152 $1,094 $1,059 5% 9% Pretax operating margin 13.5% 13.2% 13.4% 36 bps 15 bps Net income - GAAP basis $644 $430 $545 50% 18% Net income, excluding charges & credits* $644 $594 $581 8% 11% Diluted EPS - GAAP basis $0.46 $0.31 $0.39 48% 18% Diluted EPS, excluding charges & credits* $0.46 $0.43 $0.42 7% 10% North America revenue $3,189 $3,139 $2,602 2% 23% International revenue $5,215 $5,065 $5,147 3% 1% North America revenue, excluding Cameron $2,572 $2,546 $2,086 1% 23% International revenue, excluding Cameron $4,559 $4,387 $4,430 4% 3% *These are non-GAAP financial measures. See section below entitled "Charges & Credits" for details. Schlumberger Chairman and CEO Paal Kibsgaard commented, “Our third